HealthcareServices

Coagulation Factor Deficiency Market Future Outlook: Strong Growth Expected Toward $7.04 Billion by 2030

February 23, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the coagulation factor deficiency market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Coagulation Factor Deficiency Market in 2026, and what figure is it projected to hit by 2030?

The coagulation factor deficiency market has demonstrated robust growth in recent years. It is anticipated to increase from $4.93 billion in 2025 to $5.3 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. The historical surge in this market can be attributed to several factors, including enhanced diagnosis of bleeding disorders, broader availability of plasma-derived therapies, the expansion of hemophilia treatment centers, a rise in patient awareness programs, and the development of specialty healthcare services.

The coagulation factor deficiency market size is projected to witness robust expansion in the upcoming years. It is expected to swell to $7.05 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.4%. This anticipated growth can be attributed to several factors including advancements in gene therapy development, a surging demand for personalized bleeding disorder treatments, the proliferation of home care treatment models, an increasing focus on lessening treatment frequency, and escalating investments in rare disease therapeutics. Dominant trends during this forecast period are set to include the growing adoption of recombinant coagulation factors, the rising utilization of gene therapy-based treatments, an increasing inclination towards prophylactic treatment regimens, the expansion of home-based infusion therapies, and an intensified focus on long-acting factor products.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21152&type=smp

Which Drivers Are Affecting Market Participation In The Coagulation Factor Deficiency Market?

The projected expansion of the coagulation factor deficiency market is anticipated to be driven by the rising occurrence of blood-related disorders. These disorders encompass various ailments impacting the creation, operation, or makeup of blood cells, platelets, or plasma, resulting in issues like anemia, coagulation difficulties, or immune system impairments. The surge in blood-related conditions stems from factors including demographic shifts towards older populations, genetic susceptibilities, enhanced public awareness, environmental influences, evolving lifestyles, the escalating prevalence of chronic illnesses, and improved diagnostic tools enabling earlier identification. Management of blood-related disorders is aided by coagulation factor deficiency treatments, which supply vital clotting factors to avert or control excessive hemorrhage in conditions such as hemophilia, where the body’s intrinsic capacity for clot formation is compromised. For example, data from September 2024, provided by the US-based professional organization, the Leukemia and Lymphoma Society, indicates that in the US, a diagnosis of leukemia, lymphoma, or myeloma occurs Every 3 minutes. In 2024, approximately 187,740 individuals are projected to be diagnosed with these cancers, which constitutes 9.4% of the anticipated 2,001,140 new cancer cases across the US. Furthermore, as of May 2024, the UK’s government-funded healthcare system, the National Health Service (NHS) England, reported that about 17,000 people in England are currently living with sickle cell disease, an inherited blood disorder, with roughly 250 new cases identified each year. Consequently, the growing frequency of blood-related disorders is stimulating the expansion of the coagulation factor deficiency market.

What Segment Categories Are Covered In The Coagulation Factor Deficiency Market?

The coagulation factor deficiency market covered in this report is segmented –

1) By Product: Recombinant Coagulation Factor Concentrates, Plasma-Derived Coagulation Factor Concentrates, Biologics, Desmopressin, Other Product Types

2) By Deficiency Type: Haemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, Other Treatment Types

3) By End Users: Hospitals, Clinics, Home Care, Other End Users

Subsegments:

1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII, Recombinant Factor IX, Recombinant Factor VIIa

2) By Plasma-Derived Coagulation Factor Concentrates: Plasma-Derived Factor VIII, Plasma-Derived Factor IX, Plasma-Derived Factor VII

3) By Biologics: Monoclonal Antibodies, Gene Therapy Products

4) By Desmopressin: Intravenous Desmopressin, Intranasal Desmopressin

5) By Other Product Types: Fresh Frozen Plasma (FFP), Prothrombin Complex Concentrates (PCC)

How Are New Market Trends Shaping The Landscape Of The Coagulation Factor Deficiency Market?

Major companies in the coagulation factor deficiency market are concentrating on developing innovative treatments, such as one-time gene therapy, to offer long-term or potentially curative solutions for patients with bleeding disorders like hemophilia, thereby reducing the requirement for lifelong infusions of clotting factors. One-time gene therapy is defined as a medical approach that involves introducing or modifying genetic material within a patient’s cells to treat or cure a disease, aiming to provide lasting or permanent therapeutic effects after a single administration. For example, in April 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology company, announced the U.S. Food and Drug Administration (FDA) approved BEQVEZ (fidanacogene elaparvovec-dzkt) for treating adults with moderate to severe hemophilia B who currently receive factor IX (FIX) prophylaxis therapy. This is a one-time adeno-associated virus (AAV)-based gene therapy designed to introduce a functional copy of the FIX gene, encoding a high-activity FIX variant, into transduced cells. For individuals with hemophilia B, this one-time gene therapy enables them to produce FIX themselves, eliminating the need for frequent FIX infusions.

Which Key Market Players Are Investing In Expansion And Innovation Within The Coagulation Factor Deficiency Market?

Major companies operating in the coagulation factor deficiency market are Pfizer Inc., Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Novo Nordisk A/S, Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Swedish Orphan Biovitrum AB, Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., LFB S.A., Biotest AG, BioMarin Pharmaceutical Inc., uniQure, Prothya Biosolutions, Bio Products Laboratory Ltd, Green Cross Corporation, Freeline Therapeutics, Aptevo Therapeutics, Hema Biologics LLC, Generation Bio Co, Intellia Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/coagulation-factor-deficiency-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Coagulation Factor Deficiency Market?

North America was the largest region in the coagulation factor deficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation factor deficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Coagulation Factor Deficiency Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21152&type=smp

Browse Through More Reports Similar to the Global Coagulation Factor Deficiency Market 2026, By The Business Research Company

Hemostasis Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemostasis-products-global-market-report

Coagulation Analyzer Market Report 2026

https://www.thebusinessresearchcompany.com/report/coagulation-analyzer-global-market-report

Point Of Care Poc Coagulation Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-poc-coagulation-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795